Get notified when IKT files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- We Will Need to Raise Substantial Additional Capital In Order to Do So. (new) — The company explicitly states that current funding will not be sufficient to reach regulatory approval and commercialization, requiring substantial additional capital raises.
- 119,591,301 Shares of Our Common Stock Issuable Upon the Exercise of Outstanding Warrants, As of September 30, 2025, At a Weighted Average Exercise Price of $1.53 Per Share (new) — The number of shares underlying outstanding warrants exceeds the current shares outstanding, indicating a large overhang that could cause significant dilution to new investors.
Inhibikase Therapeutics files preliminary prospectus for common stock and pre-funded warrants offering, terms not yet set
Filed November 20, 2025 · ~2 min read
Key Changes
-
high
The company is offering common stock and pre-funded warrants, but the prospectus supplement leaves all pricing, share counts, and proceeds blank.
The Offering verify on EDGAR → -
high
Net proceeds will be used primarily for general corporate purposes, including clinical development of IKT-001, with broad management discretion.
Use of Proceeds verify on EDGAR → -
medium
As of September 30, 2025, the company had $77.3 million in cash, cash equivalents, and marketable securities.
Use of Proceeds verify on EDGAR →
3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (SAR 10-Q) is open in full — no account needed.
Partner
Trade IKT commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify